Clinical trials: Acute Myeloid Leukemia (AML)
Relapsed or Refractory Acute Myeloid Leukemia
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia
- Trial name
- NCT05726110
- Testing
- Selinexor, Homoharringtonine, Daunorubicin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanxi Bethune Hospital
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more…
- Conditions
- Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00003960
- Testing
- busulfan, cyclophosphamide, methylprednisolone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Myeloid Leukemia, Precursor-cell Lymphoblastic Leukemia-Lymphoma
Prevention of Left Ventricular Dysfunction During Chemotherapy
The investigators' objective is to assess the efficacy of the combined treatment with enalapril and carvedilol in the prevention of left ventricular systolic dysfunction in patients with hematological malignancies submitted to…
- Conditions
- Acute Myeloid Leukemia, Precursor-cell Lymphoblastic Leukemia-Lymphoma, Lymphoid Neoplasm, Multiple Myeloma
- Trial name
- OVERCOME (NCT01110824)
- Testing
- Enalapril and carvedilol
- Where
- 2 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Hospital Clinic of Barcelona
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
This clinical trial studies gemtuzumab ozogamicin in treating patients with relapsed or refractory acute myeloid leukemia or acute promyelocytic leukemia.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT01869803
- Testing
- gemtuzumab ozogamicin, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Leukemia, Lymphoma
LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
RATIONALE: LMB-2 immunotoxin can locate cancer cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of LMB-2 immunotoxin in treating young patients with relapsed…
- Trial name
- NCT00085150
- Testing
- LMB-2 immunotoxin
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
The main purpose of this study are to determine the recommended Phase 2 dose(s) (RP2D) route of administration, schedule and the maximum tolerated dose (MTD) in Part 1 and to determine the safety and tolerability of JNJ-67571244…
- Trial name
- NCT03915379
- Testing
- JNJ-67571244
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Hematologic Neoplasms
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
This study will determine the maximum tolerated dose of RO5045337 and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with hematologic neoplasms.
- Trial name
- NCT00623870
- Testing
- RO5045337
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia
AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells
AML is one of the most aggressive forms of leukemia, where bone marrow transplantation remains the gold standard treatment, with its known associated toxicities and related mortality.
- Trial name
- CAR-LAM (NCT04169022)
- Testing
- Sample collection
- Where
- France
- Volunteers
- 86 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Tacrolimus and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by donor stem cell transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00096096
- Testing
- mycophenolate mofetil, tacrolimus
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a)
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
This phase I trial studies the side effects of donor stem cell transplant in treating patients with high risk acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2)
- Trial name
- NCT01801046
- Testing
- mitoxantrone hydrochloride, cytarabine, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).
- Trial name
- NCT05703542
- Testing
- BXCL701
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Eric Stephen Winer, MD
Acute Myeloid Leukemia
A Patient-Centered Communication Tool (UR-GOAL) Versus Usual Care for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists
The objective of this study is to evaluate the preliminary efficacy of the UR-GOAL tool in improving shared decision making and communication between older patients with AML and their oncologists in a pilot randomized trial.
- Trial name
- UR-GOAL 2 (NCT05335369)
- Testing
- UR-GOAL
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- University of Rochester
Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM)
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
This study is evaluating the safety, pharmacokinetic profile and efficacy of venetoclax under a once daily dosing schedule in Japanese participants with hematological malignancies.
- Conditions
- Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Trial name
- NCT02265731
- Testing
- azacitadine, venetoclax, rituximab / IDEC-C2B8
- Where
- 14 sites in Japan
- Volunteers
- 38 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
The main objective of this study is to assess the biological activity of elacytarabine in combination with idarubicin in patients with acute myeloid leukaemia who has failed the first course of a remission-induction treatment…
- Trial name
- NCT01035502
- Testing
- Elacytarabine plus idarubicin
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 51 people
- Sponsor
- Clavis Pharma
Acute Myeloid Leukemia
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
To compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia
- Trial name
- NCT06451861
- Testing
- Chidamide, Venetoclax, azacitidine
- Where
- 13 sites in China
- Volunteers
- 240 people
- Sponsor
- Guangdong Provincial People's Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
This is a phase 1 study of investigational drug CFI-400945 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT03187288
- Testing
- CFI-400945 Fumarate
- Where
- 2 sites in Canada
- Volunteers
- 13 people
- Sponsor
- University Health Network, Toronto
Leukemia, Lymphoma
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Graft Versus Host Disease
- Trial name
- NCT00003056
- Testing
- cyclosporine, cyclosporine and methotrexate
- Where
- 13 sites in United States, Australia
- Volunteers
- 105 people
- Sponsor
- Baxalta now part of Shire
Acute Lymphoblastic Leukemia, Acute Leukemias
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Leukemias, Acute Myeloid Leukemia
- Trial name
- NCT07295951
- Testing
- 14C-bleximenib, bleximenib
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Janssen Research & Development, LLC
Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome)
A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT
To explore the safety and efficacy of selinexor combined with azacitidine as post-transplant maintenance therapy for TP53-mutated AML/MDS.
- Trial name
- TP53 (NCT07779031)
- Testing
- Azacitidine (AZA) Days 1 - 5, Selinexor
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Liping Dou
Acute Myeloid Leukemia
Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy
The optimal induction chemotherapy regimen for newly diagnosed elderly AML patients who are eligible for intense chemotherapy is currently not well defined.
- Trial name
- NCT06066242
- Testing
- Different induction chemotherapy regimens
- Where
- China
- Volunteers
- 113 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China